Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?
European Thyroid Journal · 2025
DOI: 10.1530/etj-24-0332 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Thyroid Journal, 2025. Verfasst von Tommaso Porcelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, University of Naples "Federico II", Naples, Italy. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Protein Kinase Inhibitors, Iodine Radioisotopes. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Università degli Studi di Napoli Federico II, Fondazione AIRC per la ricerca sul cancro ETS.
Abstract (Originalsprache)
Objective
To analyse at our institution the criteria for selecting a first-line therapy for patients with advanced radioiodine-refractory thyroid cancer and their clinical responses, safety and survival outcomes. Patients and methods We extracted data from 69 consecutive patients referred to Federico II University Hospital from September 2016 to September 2024, among whom 44 patients were treated with TKIs as first-line treatment and outside any clinical trial, and form the basis of this report.
Results
Thirty-one (71%) patients were treated with the antiangiogenesis inhibitor lenvatinib and 13 (29%) were treated with selective tyrosine kinase inhibitors (s-TKIs). Among the latter, eight patients were treated with dabrafenib + trametinib (DT), two patients were treated with selpercatinib because of contraindications to lenvatinib, and three patients received DT as redifferentiation therapy. A RECIST partial response was observed in 28% of patients treated with lenvatinib, in 63% of those treated with DT and in one of the two patients treated with selpercatinib. Grade ≥3 adverse events occurred in 13 (42%) patients treated with lenvatinib and only in 1 (9%) patient treated with DT. Progression-free survival (PFS) and overall survival rates at 1 year were 72% and 83% in lenvatinib-treated patients and 69% and 83% in DT-treated patients, respectively. In both selpercatinib-treated patients, the PFS at data cut-off was 10 months. No treatment-related deaths were observed.
Conclusion
S-TKIs permitted tailoring systemic treatment based on disease location, tumour volume and patient comorbidities, achieving satisfactory tolerance and outcomes in selected patients with an actionable driver mutation and with contraindications to angiogenesis inhibitors or candidates for redifferentiation therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, University of Naples "Federico II", Naples, Italy.
- Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
- Department of Endocrine Oncology, Gustave Roussy Cancer Centre and University Paris-Saclay, Villejuif, France.
ORCID-Profile: Tommaso Porcelli
Förderung
- Università degli Studi di Napoli Federico II
- Fondazione AIRC per la ricerca sul cancro ETS
Zitieren
APA
Porcelli, T., Luongo, C., Cerbone, A., Di Luccio, C., Nacchio, M., De Stefano, M. A., Schlumberger, M., & Salvatore, D. (2025). Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?. European Thyroid Journal. https://doi.org/10.1530/etj-24-0332
Vancouver
Porcelli T, Luongo C, Cerbone A, Di Luccio C, Nacchio M, De Stefano MA, et al. Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?. European Thyroid Journal. 2025. doi:10.1530/etj-24-0332
BibTeX
@article{Porcelli2025,
author = {Porcelli, Tommaso and Luongo, Cristina and Cerbone, Anna and Di Luccio, Carmine and Nacchio, Mariantonia and De Stefano, Maria Angela and Schlumberger, Martin and Salvatore, Domenico},
title = {Did selective kinase inhibitors change the management of patients with radioiodine-refractory thyroid cancer?},
journal = {European Thyroid Journal},
year = {2025},
doi = {10.1530/etj-24-0332}
}
EUVIMED